By Justin Petrone

Investment firm Leerink Swann has lowered its growth expectations for microarray sales worldwide based on a recent survey, its own analysis, and anecdotal information.

The company, which disclosed its findings in a research note last week, also reduced its 2011 forecast for Illumina's microarray business but maintained its previous forecast of a single-digit decline for Affymetrix.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.